Form 4: BioXcel Therapeutics Executive Frank Yocca Reports Stock Unit Vesting
SEC Form 4 Filing
Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, reports the vesting of restricted stock units.
Summary
- Frank Yocca, the Chief Scientific Officer of BioXcel Therapeutics, Inc., filed a Form 4 detailing changes in beneficial ownership.
- On March 14, 2025, 31 restricted stock units (RSUs) vested, converting into 31 shares of common stock.
- On March 15, 2025, an additional 34 RSUs vested, converting into 34 shares of common stock.
- These RSUs were granted on March 14, 2022 (521 RSUs) and March 15, 2023 (562 RSUs) and vest over time, contingent upon continued employment.
Sentiment
Score: 5
Explanation: This is a neutral event related to executive compensation. It doesn't inherently indicate positive or negative performance.
Positives
- The vesting of RSUs indicates continued employment and contribution by a key executive.
Industry Context
This filing is a routine disclosure related to executive compensation and equity ownership, common in publicly traded companies.
Stakeholder Impact
- The vesting of RSUs may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| March 14, 2022 | Grant date of 521 RSUs, vesting quarterly. |
| March 15, 2023 | Grant date of 562 RSUs, vesting quarterly. |
| March 14, 2025 | Vesting of 31 RSUs. |
| March 15, 2025 | Vesting of 34 RSUs. |
| March 17, 2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.